Malignant, long-lasting pain is an imminent component in advanced cancer and as such sufficiently decreases the quality of life of patients. Cancer patients are equally subjected to physical as well as emotional suffering. For many decades opioids have been the mainstay analgesics for treatment of moderate to severe pain conditions. Classical opioids by exerting their analgesic action in the CNS apart from producing analgesia simultaneously cause the onset of undesirable side effects such as constipation, nausea or sedation. The major advantage is a possibility to treat pain symptoms with avoidance of minor side-effects, particularly tolerance occurring in morphine-treated patients. In clinical practice it is important for a drug to possess both a peripheral and central action. In our studies we examined the analgesic effect of a dimeric enkephalin analog-biphalin in a murine skin cancer pain model developed by an intraplantar inoculation of B16T0 melanoma cells. Animals developed robust thermal hypersensitivity in the tumor-bearing paw compared to saline-injected individuals. Biphalin produced a more robust unilateral attenuation of thermal hyperalgesia in the tumor-bearing paw as compared to the classical non-peptidic drugmorphine. Results suggest a probable involvement of the peripheral opioid receptor-mediated analgesia. Thus, biphalin, may become a useful drug in cancer pain treatment because it also shows low tolerance liability. Financial support: 6FP STREP Normolife grant (LSHC-CT-2006- 037733)
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.